obecabtagene autoleucel · Aucatzyl
Cell therapy
Evidence outlook
Approved: Acute Lymphoblastic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (2)
- Adults 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (conditional marketing authorisation)
- Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (conditional marketing authorisation)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04404660 NCT04404660 · Acute Lymphoblastic Leukemia Registry: NCT04404660 | 1/2 | Phase 1b - Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) occurring after AUTO1 infusion (Up to 24 months); Phase 2 - Cohort IIA: ORR defined as proportion of patients achieving CR or CRi as assessed by an IRRC. (Up to 24 months) 2029-06-30 | In progress: results expected 30 Jun 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, Tafasitamab, budoprutug, cemacabtagene ansegedleucel, FT819 and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Obecabtagene Autoleucel (Aucatzyl): this drug | Approved | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Approved | Multispecific antibody | CD19 x CD3 | Weak signal | NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6) | |
| Inebilizumab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Ponatinib (ICLUSIG) | Approved | Small molecule | BCR-ABL (including T315I) | Partial signal | Featured results are non-efficacy only in this race | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 2(overall) | Monoclonal antibody | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ziftomenib | Phase 1/2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1(overall) | Antibody–drug conjugate | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1(overall) | — | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1(overall) | Cell therapy | CD19 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Aucatzyl (obecabtagene autoleucel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.